CLL17

Name No. For Patients with Purpose
CLL17 20-22

Previously untreated Chronic Lymphocytic Leukaemia (CLL)

This trial will compare the efficacy of continuous ibrutinib monotherapy with fixed-duration venetoclax plus obinutuzumab and fixed-duration ibrutinib plus venetoclax in patients with previously untreated CLL